LANTHEUS RECEIVES FINAL FDA APPROVAL FOR BRAVNETSA™ (LUTETIUM LU 177 DOTATATE), THE ONLY RADIOPHARMACEUTICAL FDA HAS DETERMINED TO BE BIOEQUIVALENT AND THERAPEUTICALLY EQUIVALENT TO LUTATHERA® FOR THE TREATMENT OF GEP-NETS

Reuters · 1d ago

Please log in to view news